CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10 to 15 and May 17 to 21, 2021.
瑞士祖格和马萨诸塞州坎布里奇,2021年3月10日(环球社)--CRISPR治疗公司(纳斯达克:CRSP),一家专注于为严重疾病创造变革性的基于基因的药物的生物制药公司今天宣布,它将在2021年4月10日至15日和5月17日至21日以虚拟形式举行的美国癌症研究协会(AACR)年会上展示海报。
Title:CD70 knockout: A novel approach to augment CAR-T cell function
标题:CD70基因敲除:增强CAR-T细胞功能的新途径
Session Title:Adoptive Cell Therapy
会话标题:采用细胞疗法
Session Category:Immunology
会话类别:免疫学
Abstract Number: 1537, e-poster
抽象数:1537,电子海报
Date and Time:Saturday, April 10, 2021, 8:30 a.m. ET via the AACR website, www.aacr.org
日期和时间:2021年4月10日(星期六)上午8:30美国东部时间通过AACR网站www.aacr.org
About CRISPR Therapeutics
CRISPR治疗公司简介
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR治疗公司是一家领先的基因编辑公司,专注于利用其专有的CRISPR/Cas9平台开发治疗严重疾病的变革性基因药物。CRISPR/CAS9是一项革命性的基因编辑技术,允许对基因组DNA进行精确的定向改变。CRISPR治疗公司已经建立了涵盖广泛疾病领域的治疗方案组合,包括血红蛋白病、肿瘤学、再生医学和罕见疾病。为了加快和扩大其努力,CRISPR治疗公司已经与包括拜耳在内的领先公司建立了战略合作关系,Vertex制药公司CRISPR治疗公司总部设在瑞士祖格,在美国设有全资子公司CRISPR治疗公司,研发业务设在马萨诸塞州剑桥,在旧金山、加利福尼亚州和英国伦敦设有业务办事处。欲获知更多信息,请访问www.crisprtx.com。
CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
CRISPR Treateutics®文字标记和设计标识是CRISPR Treateutics AG的商标和注册商标。所有其他商标和注册商标均为其各自所有者的财产。
Investor Contact:
投资者联系方式:
Susan Kim
苏珊·金
+1-617-307-7503
+1-617-307-7503
susan.kim@crisprtx.com
邮箱:susan.kim@crisprtx.com
Media Contact:
媒体联系人:
Rachel Eides
瑞秋·艾德斯
WCG on behalf of CRISPR
WCG代表CRISPR
+1-617-337-4167
+1-617-337-4167
reides@wcgworld.com
邮箱:reides@wcgworld.com
译文内容由第三方软件翻译。